



Nystatin is an antibiotic which is both fungistatic and fungicidal *in vitro* against a wide variety of yeasts and yeast-like fungi, including *Candida albicans*, *C. parapsilosis*, *C. tropicalis*, *C. guilliermondi*, *C. pseudotropicalis*, *C. krusei*, *Torulopsis glabrata*, *Trichophyton rubrum*, *T. mentagrophytes*. Nystatin acts by binding to sterols in the cell membrane of susceptible species resulting in a change in membrane permeability and the subsequent leakage of intracellular components. On repeated subculturing with increasing levels of nystatin, *Candida albicans* does not develop resistance to nystatin. Generally, resistance to nystatin does not develop during therapy. However, other species of *Candida* (*C. tropicalis*, *C. guilliermondi*, *C. krusei*, and *C. stellatoidea*) become quite resistant on treatment with nystatin and simultaneously become cross resistant to amphotericin as well. This resistance is lost when the antibiotic is removed. Nystatin exhibits no appreciable activity against bacteria, protozoa, or viruses.

## **INDICATIONS AND USAGE**

Nystatin cream is indicated in the treatment of cutaneous or mucocutaneous mycotic infections caused by *Candida albicans* and other susceptible *Candida* species.

**This cream is not indicated for systemic, oral, intravaginal or ophthalmic use.**

## **CONTRAINDICATIONS**

Nystatin cream is contraindicated in patients with a history of hypersensitivity to any of its components.

## **PRECAUTIONS**

### **General**

**Nystatin cream should not be used for the treatment of systemic, oral, intravaginal or ophthalmic infections.**

If irritation or sensitization develops, treatment should be discontinued and appropriate measures taken as indicated. It is recommended that KOH smears, cultures, or other diagnostic methods be used to confirm the diagnosis of cutaneous or mucocutaneous candidiasis and to rule out infection caused by other pathogens.

## **INFORMATION FOR THE PATIENT**

Patients using this medication should receive the following information and instructions:

1. The patient should be instructed to use this medication as directed (including the replacement of missed doses). This medication is not for any disorder other than that for which it is prescribed.
2. Even if symptomatic relief occurs within the first few days of treatment, the patient should be advised not to interrupt or discontinue therapy until the prescribed course of treatment is completed.
3. If symptoms of irritation develop, the patient should be advised to notify the physician promptly.

## **Laboratory Tests**

If there is a lack of therapeutic response, KOH smears, cultures, or other diagnostic methods should be repeated.

### **Carcinogenesis, Mutagenesis, Impairment of Fertility**

No long-term animal studies have been performed to evaluate the carcinogenic potential of nystatin. No studies have been performed to determine the mutagenicity of nystatin or the effects on male or female fertility.

### **Pregnancy**

Teratogenic Effects

#### *Category C*

Animal reproduction studies have not been conducted with any nystatin cream. It also is not known whether this cream can cause fetal harm when used by a pregnant woman or can affect reproductive capacity. Nystatin cream should be prescribed for a pregnant woman only if the potential benefit to the mother outweighs the potential risk to the fetus.

### **Nursing Mothers**

It is not known whether nystatin is excreted in human milk. Caution should be exercised when nystatin is prescribed for a nursing woman.

### **Pediatric Use**

Safety and effectiveness have been established in the pediatric population from birth to 16 years.

(See **DOSAGE AND ADMINISTRATION**.)

### **Geriatric Use**

Clinical studies with nystatin cream did not include sufficient numbers of subjects aged 65 years and older to determine whether they respond differently than younger subjects. Other reported clinical experience has not identified differences in responses between elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

## **ADVERSE REACTIONS**

The frequency of adverse events reported in patients using nystatin cream is less than 0.1%. The more common events that were reported include allergic reactions, burning, itching, rash, eczema, and pain on application.

(See **PRECAUTIONS: General**.)

## **DOSAGE AND ADMINISTRATION**

### **Adults and Pediatric Patients (Neonates and Older)**

Apply liberally to affected areas twice daily or as indicated until healing is complete.

## HOW SUPPLIED

Nystatin Cream USP is a smooth yellow to light green cream with a characteristic perfume odor.

30 g (NDC 66267-952-30) tubes providing 100,000 USP Nystatin Units per gram.

**Store at 20° to 25°C (68° to 77°F)** [see USP Controlled Room Temperature]. Avoid freezing.

Mfd. by: Taro Pharmaceuticals Inc., Brampton, Ontario, Canada L6T 1C1

Dist. by: **Taro Pharmaceuticals U.S.A., Inc.**, Hawthorne, NY 10532

Revised: August, 2010

PK-1161-4

107

## PRINCIPAL DISPLAY PANEL - 30 g box

**NuCare Pharmaceuticals, Inc.**

NDC: 66267-952-30

**Nystatin Cream**

30g

USP, 100,000 units per gram

See manufacturer's label for full list of ingredients

Product #: R0310030

**Rx Only**

**Nystatin**  
Lot: 000000 NDC: 66267-0952-30  
MFR NDC: 51672-1289-2 Exp.: 00-00  
Serial# 0000000002

**Nystatin**  
Lot: 000000 NDC: 66267-0952-30  
MFR NDC: 51672-1289-2 Exp.: 00-00  
Serial# 0000000002

GTIN 00366267952309  
Serial# 0000000002  
Exp. Date 00-00  
LOT#: 000000

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

STORE AT CONTROLLED TEMPERATURE 68-77°F

Apply every \_\_\_\_\_ times a day. \_\_\_\_\_ hours

Manufactured by: Taro Pharmaceutical Ind. Ltd. Haifa Bay, Israel 26110  
Packaged By: NuCare Pharmaceuticals, Inc. Orange, CA 92867

Rev 01/01/19

WARNING: KEEP OUT OF REACH OF CHILDREN

## NYSTATIN

nystatin cream

### Product Information

<b>Product Type</b>	HUMAN PRESCRIPTION DRUG	<b>Item Code (Source)</b>	NDC:66267-952(NDC:51672-1289)
<b>Route of Administration</b>	TOPICAL		

### Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
-----------------	-------------------	----------

<b>NYSTATIN</b> (UNII: BDF1O1C72E) (NYSTATIN - UNII:BDF1O1C72E)	NYSTATIN	100000 [USP'U] in 1 g
---	----------	-----------------------

### Inactive Ingredients

Ingredient Name	Strength
<b>PETROLATUM</b> (UNII: 4T6H12BN9U)	
<b>GLYCERYL MONOSTEARATE</b> (UNII: 230OU9XXE4)	
<b>CETEARETH-15</b> (UNII: 867H4YOZ8Z)	
<b>WATER</b> (UNII: 059QF0KO0R)	
<b>PROPYLENE GLYCOL</b> (UNII: 6DC9Q167V3)	
<b>METHYLPARABEN</b> (UNII: A2I8C7HI9T)	
<b>PROPYLPARABEN</b> (UNII: Z8IX2SC1OH)	
<b>TITANIUM DIOXIDE</b> (UNII: 15FIX9V2JP)	
<b>ALGELDRATE</b> (UNII: 03J11K103C)	
<b>SORBITOL</b> (UNII: 506T60A25R)	
<b>SODIUM HYDROXIDE</b> (UNII: 55X04QC32I)	

### Product Characteristics

<b>Color</b>	yellow (smooth yellow to light green)	<b>Score</b>	
<b>Shape</b>		<b>Size</b>	
<b>Flavor</b>		<b>Imprint Code</b>	
<b>Contains</b>			

### Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:66267-952-30	30 g in 1 BOX; Type 0: Not a Combination Product	08/24/2017	

### Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA064022	01/28/1993	

**Labeler** - NuCare Pharmaceuticals,Inc. (010632300)

### Establishment

Name	Address	ID/FEI	Business Operations
NuCare Pharmaceuticals, Inc.		010632300	relabel(66267-952)